Nanoparticles Could Be Tiny Cancer Assassins
One type of nanoparticle currently in development engages in “active targeting,” or targeting drugs to cancer cells by attaching them to a molecule that the cancer cell is receptive to.
Articles by vanderson
A Potential New Treatment for Sepsis
An international research team recently reported a breakthrough in the treatment of a life-threatening condition that affects approximately 20 million people per year.
Urologix and Uroplasty: Treatments for Common Urinary Disorders
Voiding the bladder is one of the most basic human functions, so mundane that we pay it little mind most of the time.
Bypassing Gastric Bypass Surgery
A number of companies are developing minimally invasive devices that produce the weight-reducing effects of a gastric bypass minus the actual surgery.
Workflow Software Can Act As Efficiency Expert for Healthcare Providers
Each patient who steps into a hospital brings along a complicated tangle of data: current health complaints, medical history, allergies, medication lists and more.
Axial Biotech Aims to Predict Scoliosis Progression With DNA Test
Adolescent idiopathic scoliosis tends to run in families, but determining which patients will develop severe spinal curvature is an inexact science.
Brain Cancer Vaccine Extends Survival Rate In Small Trial
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
It’s a Tanning Spray. No, It’s a Surgical Glue.
A compound found in sunless tanning spray may help heal post-surgical wounds.
Vertex Announces Positive Phase III Data for Hepatitis Drug
The New York Times reports that about 75 percent of patients taking telaprevir in combination with existing hepatitis C drugs were essentially cured of the virus, compared to 44 percent on standard therapy alone.
Find Out Which Companies Are Presenting at OneMedForum New York 2010
OneMedPlace has announced the first 38 companies to be presenting at the OneMedForum New York 2010 investor conference on June 29-30.